ofloxacin has been researched along with Moraxella Infections in 3 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study assessed daily aspirate samples from an indwelling sinus catheter during high-dose, short-course levofloxacin (750 mg daily x 5 days) treatment of acute maxillary sinusitis." | 9.12 | Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. ( Ambrose, PG; Anon, JB; Jones, RN; Kahn, JB; Paglia, M; Xiang, J, 2007) |
| "The authors had for aim to evaluate the efficacy and tolerance of oral levofloxacin (500 mg once a day during ten days), as a treatment for acute bacterial sinusitis at risk for complications in adult patients." | 9.11 | [Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications]. ( Gehanno, P; Pessey, JJ; Serrano, E, 2005) |
| "This study assessed daily aspirate samples from an indwelling sinus catheter during high-dose, short-course levofloxacin (750 mg daily x 5 days) treatment of acute maxillary sinusitis." | 5.12 | Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. ( Ambrose, PG; Anon, JB; Jones, RN; Kahn, JB; Paglia, M; Xiang, J, 2007) |
| "The authors had for aim to evaluate the efficacy and tolerance of oral levofloxacin (500 mg once a day during ten days), as a treatment for acute bacterial sinusitis at risk for complications in adult patients." | 5.11 | [Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications]. ( Gehanno, P; Pessey, JJ; Serrano, E, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ottaviani, S | 1 |
| Kemiche, F | 1 |
| Thibault, M | 1 |
| Cerf-Payrastre, I | 1 |
| Pertuiset, E | 1 |
| Gehanno, P | 1 |
| Pessey, JJ | 1 |
| Serrano, E | 1 |
| Anon, JB | 1 |
| Paglia, M | 1 |
| Xiang, J | 1 |
| Ambrose, PG | 1 |
| Jones, RN | 1 |
| Kahn, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Multi-center, Non-comparative Sinus Puncture Study of 750 mg, Short-course Levofloxacin in the Treatment of Acute Maxillary Sinusitis[NCT00236652] | Phase 3 | 18 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ofloxacin and Moraxella Infections
| Article | Year |
|---|---|
[Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications].
Topics: Acute Disease; Adolescent; Adult; Africa, Southern; Aged; Bacterial Infections; Female; France; Haem | 2005 |
Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Catheters, Indwelling; Dose-Response Relationship, Drug | 2007 |
1 other study available for ofloxacin and Moraxella Infections
| Article | Year |
|---|---|
Polyarticular septic arthritis due to Moraxella canis revealing multiple myeloma.
Topics: Animals; Anti-Bacterial Agents; Arthritis, Infectious; Cefotaxime; Diagnosis, Differential; Disease | 2009 |